Background. This study evaluates the association between estimated GFR (eGFR) at the start of dialysis and mortality within Europe. Methods. Renal registries participating in the ERA-EDTA Registry were asked to provide data on serum creatinine recorded 0-4 weeks before the start of dialysis in incident dialysis patients in 1999 and 2003. Within this cohort study, data were available in 11 472 patients from nine national or regional European renal registries. Cox regression analyses were performed to examine the association between GFR estimated by the four-variable MDRD equation (eGFR) and all-cause mortality, using a follow-up through 31 December 2005. Results. In the 2003 data, the mean eGFR was 8.6 ml/min/1.73 m 2 . The unadjusted survival analyses showed that an increase in eGFR of 1 ml/min/1.73 m 2 was associated with a higher mortality risk (HR = 1.03; 95% CI: 1.03-1.04) that remained similar after adjustment for age, gender, primary renal disease, treatment modality, country and comorbidity. The findings were consistent across gender, treatment modalities, geographical regions and time periods (2003 versus 1999), but the association between a higher eGFR at the start of dialysis and mortality was the strongest in the youngest age groups and in patients with glomerulonephritis. Analyses at centre level showed that a 10% increase in the percentage of patients starting dialysis at high eGFR levels (≥10.5 ml/min) was associated with a 22% higher mortality risk (HR = 1.22; 95% CI: 1.18-1.26).
Introduction
Both the American [1, 2] and European [3] clinical practice guidelines have recommendations regarding the timing of the initiation of dialysis for patients with end-stage renal disease (Table 1 ). The European guidelines recommend that dialysis should be instituted whenever the glomerular filtration rate (GFR) is <15 ml/min and there are clinical indications (i.e. symptoms or signs of uraemia, inability to control hydration status or blood pressure or a progressive deterioration in nutritional status). In any case, dialysis should be started before the GFR has fallen to 6 ml/min/ 1.73 m 2 . Solid evidence in terms of randomized controlled trials on when to start dialysis is still lacking. Proponents of starting dialysis at higher levels of renal function advocate that this may improve nutrition and therefore may decrease hospitalization and mortality [4, 5] . Conversely, others argue that patients may be exposed to the risks and inconvenience of dialysis earlier than necessary which could have an impact on the patient's health and his (family's) quality of life.
Several observational studies have been published on the association between the level of renal function at the start of dialysis and mortality. Of these, a few small studies found a survival advantage in patients starting dialysis at a higher GFR [4, 6, 7] . Three more recent studies from the USA however found an increased risk of death in patients who started dialysis at higher GFR levels, which could only partially be 3176 V. S. Stel et al. Table 1 . American and European guidelines on the initiation of dialysis [1] [2] [3] 
Guideline
Recommendation on the timing to initiate dialysis US National Kidney Foundation Dialysis Outcomes and Quality Initiative (NKF-DOQI) [1, 2] Unless certain conditions are met, patients should be advised to initiate some form of dialysis when the weekly renal Kt/Vurea falls <2.0 (which equals to a GFR of ∼10.5 ml/min). The conditions that may indicate that dialysis is not yet necessary even though the weekly renal Kt/Vurea is <2.0 are (A) stable or increased oedema-free body weight (B) normalized protein equivalent of nitrogen appearance (nPNA) ≥ 0.8 g/ kg/day (C) complete absence of clinical signs or symptoms attributable to uraemia European Best Practice Guidelines [3] (A) Dialysis should be instituted whenever the GFR is <15 ml/min, and there is one or more of the following: symptoms or signs of uraemia, inability to control hydration status or blood pressure or a progressive deterioration in nutritional status. In any case, dialysis should be started before the GFR has fallen to 6 ml/min/1.73 m 2 , even if optimal predialysis care has been provided and there are no symptoms. (B) High-risk patients e.g. diabetes may benefit from an earlier start. (C) To ensure that dialysis started before the GFR is <6 ml/min/1.73 m 2 , clinics should aim to start at 8-10 ml/min/1.73 m 2 .
The updated version of the NFK-DOQI guideline also stated that there are theoretical considerations to support initiation of dialysis therapy at a GFR of approximately 10 mL/min/1.73 m 2 (NFK DOQI Guideline 2006, page S15) and the updated version of European Best Practice Guideline also recommends that to ensure that dialysis started before the GFR is <6 ml/min/1.73 m 2 , clinics should aim to start at 8-10 ml/min/1.73 m 2 (European Best Practice Guideline (2005)) [26] [27] [28] .
explained by higher comorbidity [8] [9] [10] . So far, within Europe, only small studies have been performed on this topic [11, 12] . The aim of this large study of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry was therefore to investigate the association between estimated GFR (eGFR) at the start of dialysis and mortality.
Methods

Population and data collection
All national and regional renal registries participating in the ERA-EDTA Registry with individual patient data at the time of the start of the study [13] were asked whether they could provide data on serum creatinine assessed 0-4 weeks before the start of dialysis in all patients who were older than 20 years of age and started dialysis in 1999 or 2003. These data were available in 11 472 patients from the registries of Belgium (Dutch and French speaking), Finland, UK (England/Wales) and from the five additional registries of Italy (Basilicata, Piedmont), Greece, Spain (Valencian region) and UK (Scotland) that collected these data retrospectively. If available, the registries provided the date of the measurement of serum creatinine, race (Caucasian: yes/no) and comorbidity at the start of dialysis, including diabetes mellitus, ischaemic heart disease, peripheral vascular disease, cerebrovascular disease and malignancy.
Analyses
To test whether the study sample was representative for all dialysis patients of the participating countries, several comparisons were made with patients in the ERA-EDTA Registry from the same study period but who were not included in the study. These comparisons included demographic variables as well as 2-year survival. Similar analyses were performed to check the representativeness of patients without a date of the measurement of serum creatinine.
In keeping with the guidelines on the initiation of dialysis [2, 3] , residual renal function was estimated by GFR (eGFR) with the four-variable Modification of Diet in Renal Disease (MDRD) equation [14] : GFR (ml/min/1.73 m 2 ) = 186. Patients were included in the study if the date of the measurement of serum creatinine was 0-4 weeks before the start of dialysis, or if the date was not known. If information on race was not available, patients were categorized as Caucasian, as the vast majority of the European dialysis population is Caucasian [15] . A Mann-Whitney test was used to compare the mean eGFR at the start of dialysis in incident patients of 2003 with 1999. ANOVA and chi-square tests were used to compare characteristics of the high eGFR group (eGFR ≥ 10.5 ml/min/1.73 m 2 ), medium eGFR group (eGFR ≥ 8 and < 10.5 ml/min/1.73 m 2 ) and low eGFR group (eGFR < 8.0 ml/min/1.73 m 2 ). These stratifications were based on the guideline cut-off points [1] [2] [3] .
Kaplan Meier and Cox regression analyses were performed on the 2003 data to examine the associations between eGFR at the start of dialysis and survival. Survival was taken from the date of start of dialysis, and also from Day 91. Survival was censored at the date of leaving the study due to a renal transplant, recovery of renal function, loss to follow-up or the end of follow-up time on 31 December 2005 (for Italy until 31 December 2004). The 2-year unadjusted survival probabilities of the high, medium and low eGFR groups were examined. Three main Cox proportional hazard regression models were built in which eGFR was treated differently: (1) eGFR as continuous variable (i.e. the association of an increase of 1 ml/min/1.73 m 2 eGFR with survival); (2) eGFR divided into three categories (i.e. high, medium and low eGFR groups); and (3) eGFR divided into seven categories. These analyses were adjusted for general characteristics, i.e. age at start of dialysis, gender, primary renal disease, first treatment modality and country. Additional adjustment for comorbidity was performed for those countries where these data were available. To test the robustness of the results, these survival analyses were repeated by age group, gender, primary renal disease, treatment modality, geographical region (as patients in Southern Europe have a better survival than those in Northern Europe [16] ) and time period, i.e. in incident patients from 1999 with a follow-up until 31 December 2001 and with a follow-up until 31 December 2005. The third main model was repeated by time period only, because of the relatively small number of patients with comorbidity data in each of the seven categories of eGFR.
The relationship between timing of initiation of dialysis and mortality is potentially confounded by indication: patients may be selected to start dialysis at higher or lower levels of GFR because of known (e.g. increased comorbidity) or unknown prognostic factors. The grouped-treatment (GT) approach tries to eliminate or at least reduce confounding by indication [17] . In our analyses, the GT variable was the percentage of patients in a centre that was categorized in the high eGFR group (i.e. ≥10.5 ml/min) at the start of dialysis in 2003. Using this method, the allocation of a centre to a patient was considered as a natural experiment, with allocation Downloaded from https://academic.oup.com/ndt/article-abstract/24/10/3175/1817957 by guest on 04 March 2019 primarily based on whether the patient lived in the vicinity of that centre. Cox regression analyses were performed as described above, including the GT variable as the only covariate. In addition, we adjusted the centre effect for differences in patient characteristics that still exist between the centres [18] . In order to get a valid estimation of the percentage of patients in the high eGFR group, centres with >30 incident patients were included for the GT analyses. SAS 9.1 was used for all analyses.
Results
Of the 16 871 dialysis patients of the participating registries older than 20 years of age, 5399 patients were excluded as no data on serum creatinine were available. Table 2 shows the baseline characteristics of the incident dialysis patients of 2003 (n = 6716) and 1999 (n = 4756). Patients started dialysis significantly at higher levels of eGFR in 2003 than in 1999 (mean eGFR of 8.6 versus 7.9 ml/min/1.73 m 2 ) (P < 0.001). In the 2003 cohort, the mean age (64.4 years) of the patients participating in this study was similar to that (63.6 years) of the nonparticipants. Additionally, the unadjusted [66.8% (95% CI: 66.0-67. assessed 0-4 weeks before the start of dialysis had a lower mean eGFR (8.3 versus 9.8 ml/min/1.73 m 2 ) and mean age (63.9 versus 65.9 year) compared to patients in which such a date was not known, but their 2-year survival was similar (66.8%: 95% CI: 65.9-67.7 versus 66.7%: 95% CI: 65.1-68.3). When excluding patients without such a date, the findings did not materially differ from those presented below.
During an average follow-up of 1.77 years and 11 873 person-years of observation, 2412 (35.9%) deaths occurred in patients who started dialysis in 2003. The unadjusted 2-year survival probabilities since the start of dialysis of the patients were 60.5% (95% CI: 59.0-62.0) for the high eGFR group, 66.0% (95% CI: 64.3-67.6) for the medium eGFR group and 69.9% (95% CI: 68.8-71.0) for the low eGFR group in the 2003 data ( Figure 1a) . Also, if early mortality was excluded, the unadjusted 2-year survival probabilities differed significantly for patients of the high, medium and low eGFR groups in the 2003 data (Figure 1b) . The patterns as shown in Figure 1a and b are almost similar after adjustment for general characteristics and comorbidity. Moreover, after adjustment for general characteristics, the survival probability since Day 91 was lower in the high eGFR group (74.4%; 95% CI: 72.2-76.8) compared to the low eGFR group (78.1%; 95% CI: 76.6-79.6). Table 3 shows the association between an increase of 1 ml/min/1.73 m 2 eGFR at the start of dialysis and survival (since Day 1). In the 2003 cohort, the unadjusted analyses showed that an increase of eGFR by 1 ml/min/1.73 m 2 was associated with a higher mortality risk (HR = 1.03; 95% CI: 1.03-1.04) that remained similar after adjustment for the general characteristics and after additional adjustment for comorbidity. The findings were consistent across gender, treatment modalities, geographical regions and time periods (2003 versus 1999) . However, the association between a higher eGFR (in ml/min/1.73 m 2 ) and mortality was the strongest in the younger age groups compared to the older age groups, and in patients with glomerulonephritis as primary renal disease compared to those with other primary renal diseases, also after adjustment for general characteristics and comorbidity. The results presented in Table 3 did not materially differ when analysing the data since Day 91 after the start of dialysis.
Patients of the low eGFR group were younger, included more females and fewer patients with diabetes mellitus as primary renal disease than patients of the high eGFR group. Table 4 shows that the death rate per 100 person-years was 25.9 in the high eGFR group and 17.9 in the low eGFR group. After adjustment for general characteristics, patients of the high eGFR group in the 2003 cohort had a higher risk of death of 1.32 (95% CI: 1.20-1.46) compared to patients of the low eGFR group. The HR remained similar after additional adjustment for comorbidity [HR = 1.38 (95% CI: 1.19-1.61)]. A positive association between eGFR at the start of dialysis and mortality risk was also found if eGFR was divided into seven categories (Table 4 ). This positive association was less pronounced in patients with diabetes mellitus as primary renal disease and more pronounced in the younger age groups and in patients with glomerulonephritis as primary renal disease after adjustment for general characteristics and comorbidity. Additional analyses in patients with glomerulonephritis as primary renal disease without reported comorbid conditions (n = 274), with adjustment for general characteristics, showed that in this group with a relatively good prognosis patients from the high eGFR group may have a higher risk of death compared to those from the low eGFR group [HR = 2.08 (95% CI: 0.79-5.48)]. Furthermore, although ∼40% of the causes of death were missing, the distribution of the causes of death (cardiovascular, cerebrovascular accident, infection, cachexia and other causes) was similar within the high, medium and low eGFR groups.
In order to try to reduce potential confounding by indication, we also performed survival analyses at the centre level. In those analyses, the percentage of patients in the high eGFR group at the start of dialysis was used to predict risk of death. The percentage of patients in the high eGFR group per centre varied from 4% to 71% (median 25%). The HR per 10 percent increase of patients in the high eGFR group was 1.22 (95% CI: 1.18-1.26) (n = 3572). Patients in centres where the percentage of high eGFR was above the median (25%) were older compared to those in the other centres (median age 70.6 versus 64.8 year), and were more often on haemodialysis (HD) (82.0% versus 71.9%), whereas the distribution of males (59.0% versus 61.5%), and patients with diabetes mellitus as primary renal disease (22.7% versus 20.9%), did not materially differ. As the difference in the median age and in the percentage of patients on HD between centres having more or less than 25% of patients in the high eGFR group was substantial, 
Discussion
The current large European registry study showed that a higher eGFR at the start of dialysis was associated with a higher mortality risk. However, several potential limitations of this study need to be considered. First, the timing of the initiation of dialysis was based on eGFR only. The US National Kidney Foundation Dialysis Outcomes and Quality Initiative (NKF-DOQI) workgroup recommends that dialysis should be started if (estimated) GFR falls <10.5 ml/ min/1.73 m 2 , unless conditions are fulfilled with respect to oedema-free body weight, malnutrition and uraemia (see Table 1 ) [1, 2] . Unfortunately, the patient's clinical condition that is taken into consideration in the guidelines and that will undoubtedly play a role in the nephrologists' decision to start dialysis could not be evaluated within this study and this may give rise to confounding by indication. In this line of reasoning, patients who started at higher levels of eGFR might not be exactly similar to those who started at lower levels of eGFR with respect to relevant prognostic factors. For example, patients with comorbidity or suffering from severe malnutrition are known to start dialysis at higher levels of renal function [19, 20] and for this reason these patients may have a higher mortality risk than those who started at lower levels of renal function. However, in line with American studies [8] [9] [10] , the current study shows that when estimating the effect of eGFR on mortality, adjustment for assessed comorbidity together with other general characteristics had an only limited effect on the hazard ratios. Moreover, other studies showed that additional adjustment for factors such as nutritional status, baseline haematocrit and bicarbonate levels, smoking, alcohol or drug dependence, dry weight, functional impairment, body mass index, EPO, AIDS, insurance status, employment also had a limited effect on the positive association between a high GFR at the start of dialysis and mortality risk [8] [9] [10] . It should be noted, however, that even after adjustment for potential confounders there is still the possibility for residual confounding, because it is not possible to adjust for confounders that were not measured (or not known), whereas other confounders could be measured insufficiently [21] . Additional analyses at centre level trying to reduce potential confounding by indication showed that centres with a higher percentage of patients categorized in the high eGFR group had a higher mortality risk, which is in line with our findings in the individual patient analysis. Although centre differences in patient characteristics may still exist (e.g. age), the large between-centre variation in the percentage of patients in the high eGFR group of 4-71% suggests that the timing of initiation of dialysis was also influenced by facility practice and not by covariates of individual patients alone. In addition, after adjustment for age and percentage of HD, we also found that centres with a higher percentage of patients categorized in the high eGFR group had a higher mortality risk. Still, randomization is the best option to try and prevent confounding by indication. Recently, a first randomized controlled trial on this topic was started in Australia and New Zealand [22] . In this study, the aim was to randomize about 800 patients to start dialysis at an eGFR by the Cockcroft-Gault equation of either 10-14 ml/min/1.73 m 2 or 5-7 ml/min/1.73 m 2 . It will take some time before its results will be available. In this respect, it is noteworthy that a recently published randomized controlled trial by Brunori et al. [23] was performed to assess the non-inferiority of diet versus dialysis in 1-year mortality including 112 uraemic patients without diabetes older than 70 years of age with a GFR of 5-7 ml/min/1.73 m 2 (calculated as the mean of creatinine clearance and urea clearance in a 24-h urine collection). They found that in this patient group, the start of dialysis treatment can be delayed for ∼1 year without increasing their risk of mortality [23] .
Second, in our study, data were available from the initiation of dialysis, and not from before that point in time. Therefore, our results may suffer from lead-time bias and survivor bias. Lead time is the time between an observation or intervention and an endpoint. In the context of dialysis initiation, patients who start with higher levels of renal function may be observed from an earlier point of disease and therefore accrue a greater apparent survival than those who start with lower level of renal function. This means that if we would have taken the lead time of these patients into account (by subtracting this extra time from their survival time), their relative risk of death would have been even higher than the one shown in this study. Survivor bias may also have occurred, because the patients who started dialysis at lower levels of eGFR may have already survived for a longer period without requiring dialysis than those who started at higher levels of eGFR, and have, therefore, selected themselves out as survivors. They may therefore not be representative of the whole group of patients starting dialysis. We were not able to record the death rate of the predialysis population. Traynor et al., however, showed that even if all patients who died before the start of dialysis were allocated to the group of patients who started at higher levels of eGFR (eGFR ≥ 8.3 ml/min, estimated by the Cockcroft-Gault equation), there would still be no survival benefit for this group of patients compared with the group of patients who started at lower levels of eGFR (eGFR < 8.3 ml/min) [12] .
Third, the most reliable method to assess serum creatinine is the enzymatic method, and results of other methods should be interpreted with caution [3] . Within clinical practice, however, the enzymatic method is only rarely used. Although data on the method to assess serum creatinine were not available per patient, we know that the Jaffe method was most often used within the participating countries. This latter method may overestimate serum creatinine to a maximum of 20% [24] meaning that the eGFR values in our patients have been somewhat underestimated.
Finally, the MDRD equation might not be valid in patients with advanced renal failure. For example, the GFR estimated by the MDRD equation might be overestimated in patients with low serum creatinine production, such as malnourished patients and/or patients with a low muscle mass [25] .
The results of our study showing that a higher eGFR at the start of dialysis was associated with a higher mortality risk are in line with the results from three large studies from the USA [8] [9] [10] . Fink et al. showed in a study of 5388 dialysis patients that the creatinine level was inversely associated with a mortality risk (RR = 0.96; 95% CI: 0.93-0.99) and that this relationship sustained if the GFR was estimated with the MDRD equation, even after adjustment for potential confounders [9] . A study of Kazmi et al., including >3 00 000 patients, found that the hazard ratio for death for each 1 ml/min greater GFR at the initiation of dialysis estimated with the MDRD equation was 1.03 (95% CI: 1.03-1.04) even after adjustment for general characteristics including comorbid conditions, which was consistent across subgroups [10] . In a study of almost 3000 patients, Beddhu et al. showed that each 5 ml/min increase of GFR estimated with the MDRD equation was associated with a 28% higher risk of death (RR = 1.28; 95% CI: 1.12-1.46) [8] .
Within Europe, two small studies were performed. Korevaar et al. included 253 incident patients on dialysis in The Netherlands, and showed that the gain of 2.5 months in survival of patients who started dialysis with a relatively high GFR calculated as the mean of creatinine and urea clearance was most likely a reflection of the lead time instead of a real advantage of a timely start [11] . Traynor et al. were able to avoid potential bias arising from late referral as well as lead-time bias as a result of their study design [12] . They did not find any survival advantage for 119 patients who received dialysis at higher levels of eGFR (eGFR ≥ 8.3 ml/min, estimated by the Cockcroft-Gault equation) compared to 116 patients who started dialysis at lower levels of eGFR (eGFR < 8.3 ml/min). In this study, a higher level of 1 ml/min eGFR at the start of dialysis was associated with a poorer outcome (HR = 1.1, P = 0.02).
This first large European study, including >11 000 patients, also found that a higher level of renal function at the start of dialysis was associated with a higher mortality risk. However, as this study may suffer from using uncalibrated creatinine measurements and the MDRD equation that may not reliably estimate the level of renal function, from confounding by indication and from survivor bias, our data are insufficient to answer the question of when to start dialysis. Only after the publication of the results of the randomized controlled trial comparing the survival of dialysis patients who started at high and low levels of renal function, we may be able to assess to what extent observational studies like ours suffer from confounding by indication.
Conclusion
This large European study showed that a higher eGFR at the start of dialysis was associated with a higher mortality risk, which is in line with earlier findings from the USA. Unfortunately, the patient's clinical condition that is taken into consideration in the guidelines and that will undoubtedly play a role in the nephrologists' decision to start dialysis could not be evaluated within this study and this may give rise to confounding by indication. Although analyses at centre level, which tend to reduce confounding by indication, confirmed the results of the individual patient-based analyses, this observational study, like other observational studies on the effects of therapy, may still be subject to confounding by indication, which might be substantial. Therefore, an evidence-based answer to the question when to start dialysis will need to come from sufficiently powered randomized controlled trials in a broad patient population.
